Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immune cell therapies - Creative Medical Technology Holdings

Next Previous
Drug Profile

Research programme: immune cell therapies - Creative Medical Technology Holdings

Alternative Names: adoptive immunotherapy; CELZ-101; IMMCELZ; reprogrammed immune cells; reprogrammed T cells

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Creative Medical Technology Holdings
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Hepatocyte growth factor modulators; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Heart failure; Liver failure; Parkinson's disease; Renal failure; Rheumatoid arthritis; Stroke; Type 1 diabetes mellitus

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Heart-failure in USA (Parenteral)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Liver-failure in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top